Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Pasotuxizumab, a Bite ® Immune Therapy for Castration-Resistant Prostate Cancer: Phase I, Dose-Escalation Study Findings

by Wittemer-Rump, Sabine , Goebeler, Maria-Elisabeth , Stienen, Sabine , Miller, Kurt , Buck, Andreas , de Santis, Maria , Koca, Gökben , Hummel, Horst-Dieter , Dittrich, Christian , Kufer, Peter , Bargou, Ralf C , Seggewiss-Bernhardt, Ruth , Ajavon-Hartmann, Antoinette , Finnern, Ricarda , Deschler-Baier, Barbara , Kusi, Helena , Thurner, Annette , Loidl, Wolfgang , Döcke, Wolf-Dietrich , Lapa, Constantin , Boix, Oliver , Sayehli, Cyrus Michael , Chatterjee, Manik , Polat, Bülent , Grüllich, Carsten

in Aged / Aged, 80 and over / Androgens / Antibodies / Antibodies, Bispecific - immunology / Antibodies, Bispecific - pharmacokinetics / Antibodies, Bispecific - therapeutic use / Antigens / Antigens, Surface - immunology / Antineoplastic Agents, Immunological - immunology / Antineoplastic Agents, Immunological - pharmacokinetics / Antineoplastic Agents, Immunological - therapeutic use / Biomarkers / Biomarkers, Tumor - blood / Bisphosphonates / Castration / CD3 Complex - immunology / Cytokines / Dosage / Glutamate Carboxypeptidase II - immunology / Humans / Immunotherapy / Infusions, Intravenous / Injections, Subcutaneous / Intravenous administration / Lymphocytes / Lymphocytes T / Male / Maximum Tolerated Dose / Medical prognosis / Metastasis / Middle Aged / Patients / Pharmacokinetics / Prostate cancer / Prostatic Neoplasms, Castration-Resistant - blood / Prostatic Neoplasms, Castration-Resistant - immunology / Prostatic Neoplasms, Castration-Resistant - pathology / Prostatic Neoplasms, Castration-Resistant - therapy / Solid tumors / Treatment Outcome / Tumor cells / Tumors

2021

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Pasotuxizumab, a Bite ® Immune Therapy for Castration-Resistant Prostate Cancer: Phase I, Dose-Escalation Study Findings

2021

Confirm

Do you wish to request the book?

Pasotuxizumab, a Bite ® Immune Therapy for Castration-Resistant Prostate Cancer: Phase I, Dose-Escalation Study Findings

2021

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Pasotuxizumab, a Bite ® Immune Therapy for Castration-Resistant Prostate Cancer: Phase I, Dose-Escalation Study Findings

Wittemer-Rump, Sabine,

Goebeler, Maria-Elisabeth,

Stienen, Sabine,

Miller, Kurt,

Buck, Andreas,

de Santis, Maria,

Koca, Gökben,

Hummel, Horst-Dieter,

Dittrich, Christian,

Kufer, Peter,

Bargou, Ralf C,

Seggewiss-Bernhardt, Ruth,

Ajavon-Hartmann, Antoinette,

Finnern, Ricarda,

Deschler-Baier, Barbara,

Kusi, Helena,

Thurner, Annette,

Loidl, Wolfgang,

Döcke, Wolf-Dietrich,

Lapa, Constantin,

Boix, Oliver,

Sayehli, Cyrus Michael,

Chatterjee, Manik,

Polat, Bülent,

Grüllich, Carsten

2021

Overview

We report results of a first-in-human study of pasotuxizumab, a PSMA bispecific T-cell engager (BiTE ) immune therapy mediating T-cell killing of tumor cells in patients with advanced castration-resistant prostate cancer. We assessed once-daily subcutaneous (SC) pasotuxizumab. All SC patients developed antidrug antibodies; therefore, continuous intravenous (cIV) infusion was assessed. A total of 47 patients received pasotuxizumab (SC: n = 31, 0.5-172 μg/d; cIV: n = 16, 5-80 μg/d). The SC maximum tolerated dose was 172.0 μg/d. A sponsor change stopped the cIV cohort early; maximum tolerated dose was not determined. PSA responders occurred (>50% PSA decline: SC, n = 9; cIV, n = 3), including two long-term responders. Data support pasotuxizumab safety in advanced castration-resistant prostate cancer and represent evidence of BiTE monotherapy efficacy in solid tumors. Clinical trial registration: NCT01723475 (ClinicalTrials.gov).

Share this book

Add to My Shelf

Publisher

Future Medicine Ltd

Subject

/ Antibodies, Bispecific - immunology

/ Antibodies, Bispecific - pharmacokinetics

/ Antibodies, Bispecific - therapeutic use